Primary large cell neuroendocrine carcinoma of the ovary: A rare entity.

Gulf J Oncolog

Laboratory of Cytology and Histopathology Moulay Driss 1st, Casablanca, Morocco.

Published: January 2021

Background: Large-cell neuroendocrine carcinoma (LCNEC) of the ovary is rare, highly aggressive tumor and diagnosed at advanced stages. Immunohistochemistry is required for the diagnosis. The optimal treatment management is not codified because of its rarity.

Case Presentation: We report the case of a 36-year-old woman with a locally advanced stage LCNEC of the ovary managed by surgery and adjuvant chemotherapy with etoposide and cisplatin. She remained disease free until now four years after the end of chemotherapy.

Conclusion: This report suggests the necessity of immunohistochemical analysis in the diagnosis of LCNEC of the ovary. Due to the rarity of LCNC, the general consensus on treatment is not standardized. We used adjuvant chemotherapy regimen similar to large cell carcinoma of the lung.

Download full-text PDF

Source

Publication Analysis

Top Keywords

lcnec ovary
12
large cell
8
neuroendocrine carcinoma
8
ovary rare
8
adjuvant chemotherapy
8
primary large
4
cell neuroendocrine
4
ovary
4
carcinoma ovary
4
rare entity
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!